R&D Advances in immunosuppression research may bring transplant ... There has been little innovation in immunosuppression therapy for organ transplant patients over the past 30 years.
Partner Content Partner Content Only four weeks till SMi’s 3D Cell Culture Conference 2019 Only four weeks till SMi’s 3D Cell Culture
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
